A Phase 1/2 interventional study of Xenon in Autism Spectrum Disorder (ASD) and Autism, sponsored by The Children's Hospital of Zhejiang University School of Medicine. Not yet recruiting at 1 site in China. Open to participants aged 4 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by The Children's Hospital of Zhejiang University School of Medicine · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Autistic Disorder with a site in China — 13 open to participants now, 15 under way, none of them phase 3. Autistic Disorder · China.
Among the 26 studies in Autistic Disorder with a site in China, this one is the 10th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 1/2, reaches primary completion later than 8 of the 14 other live ones, and was the 21st registered.
1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.
Browse Autistic Disorder studies →13 of the 26 studies in Autistic Disorder with a site in China are open now. Recruiting first, the newest first:
Children's Hospital of Fudan University · Sites in China
Ages 18 mo–24 mo · Healthy volunteers
Children's Hospital of Fudan University · Sites in China
Ages 3–10
Children's Hospital of Fudan University · Sites in China
Ages 2–17 · Healthy volunteers
Children's Hospital of Fudan University · Sites in China
Ages 1 mo–18 yrs
Central South University · Sites in China
Ages 3–18
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 184 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 144 (78%) stop at 75 or younger; 150 take children under 18; 56 take healthy volunteers.
This study: 4 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 2 · Phase 3 1
First in 2009; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 72 is above the median of 50 across 814 interventional studies indexed under Autistic Disorder.
Median enrollment 66 across the 20 interventional studies, 340 across the 6 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 26 have an industry lead sponsor. The 10 most frequent:
The Children's Hospital of Zhejiang University School of Medicine is the lead sponsor of 69 studies on the registry; 52 are open to participants now.
The Children's Hospital of Zhejiang University School of Medicine has 1 study filed under Autistic Disorder — fewer than ten, so there is no comparison to draw.
4 of the studies in Autistic Disorder with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06112067Shanghai Mental Health CenterEfficacy and Safety of Combo-stim Deep Brain Stimulation for Treatment-refractory Mental Disorders | 2026-11 |
| NCT07509879Qilu Hospital of Shandong UniversityResearch on the Molecular Mechanism of Cognitive Differences Between Williams Syndrome and Autism Spectrum Disorder | 2026-12-01 |
| NCT05901558Children's Hospital of Fudan UniversityStrategies for Toddler ASD With Remote-therapy (STAR) Model for ASD | 2026-12-30 |
| NCT07435103The Children's Hospital of Zhejiang University School of MedicineXenon Therapy for Children With Autism Spectrum Disorder | 2027-03-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 26 studies in Autistic Disorder with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the efficacy and safety of inhaled xenon for the treatment of children with autism spectrum disorder (ASD). The primary objective is to determine whether short-term inhalational xenon therapy can improve social functioning in children with ASD, as measured by changes in the Social Responsiveness Scale (SRS). Safety and tolerability of xenon inhalation in the pediatric population will also be assessed.
In this randomized, placebo-controlled trial, participants will receive either inhaled xenon or a placebo gas (medical air without xenon) to compare treatment effects.
Participants will:
Inhale 25% xenon or placebo for 10 minutes per day for 10 consecutive days Attend two clinical visits: one immediately after completion of the intervention and one at 3 months post-intervention for follow-up assessments and safety evaluations
1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.
This study's planned enrollment of 72 is above the median of 50 across 814 interventional studies indexed under Autistic Disorder.
Browse Autistic Disorder studies →The Children's Hospital of Zhejiang University School of Medicine is the lead sponsor of 69 studies on the registry; 52 are open to participants now.
Compared within Autistic Disorder, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autism Spectrum Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children aged 4-8 years with autism spectrum disorder in the control group underwent a daily 10-minute inhalation of 30% oxygen (delivered via face mask at 2 L/min) for 10 consecutive days.
Drug: Xenon
Children aged 4-8 years with autism spectrum disorder in the treatment group underwent a daily 10-minute inhalation of 25% Xenon (delivered via face mask at 2 L/min) for 10 consecutive days.
Drug: Xenon
Children aged 4-18 with autism spectrum disorder inhaled a mixture of 25% Xenon via a face mask at an oxygen flow rate of 2 L/min, for 10 minutes per day for 10 day.
Also known as: Xe
Core symptom outcomes
For the assessment of core symptom outcomes, the social responsiveness scale, Second Edition was used.Raw scores were converted to age- and sex-normed T-scores, with a minimum obtainable T-score of 30. A total T-score of 60 or higher indicates clinically significant symptom severity, whereas T-scores of 59 or below are considered within the normal range.
Time frame: From enrollment to the end of treatment at 3 months.
Core symptom outcomes
For the assessment of core symptom outcomes, the Autism Diagnostic Observation Schedule (ADOS-2) was used.
Time frame: From enrollment to the end of treatment at 3 months.
Aberrant behavior outcomes
For the assessment of aberrant behavior outcomes, the Aberrant behavior Checklist (ABC) scale was used.
Time frame: From enrollment to the end of treatment at 3 months.
Treatment efficacy
For the assessment of treatment efficacy, the Autism Treatment Evaluation Checklist scale was used. The Autism Treatment Evaluation Checklist total score ranges from a minimum of 0 (no autism symptoms) to a maximum of 179 (severe impairment), with lower scores indicating fewer symptoms and higher scores indicating greater severity.
Time frame: From enrollment to the end of treatment at 3 months.
Severity
For the assessment of behavioral severity, the Clinical Impressions Severity of illness (CGI-S) was used.
Time frame: From enrollment to the end of treatment at 3 months.
Improvements
For the assessment of behavioral improvements after treatment, the Clinical Global Impressions scale for Improvement (CGI-I) scale was used.The Clinical Global Impressions-Improvement scale is a 7-point scale ranging from 1 ("Very much improved") to 7 ("Very much worse"), with a score of 4 indicating "No change."
Time frame: From enrollment to the end of treatment at 3 months.
Sleep problems
For the assessment of sleep problems, the Children's Sleep Habits Questionnair (CSHQ) was used.
Time frame: From enrollment to the end of treatment at 3 months.
Brain functions
For the assessment of brian functions, the MRI imaging was used.
Time frame: From enrollment to the end of treatment at 3 months.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2026; primary completion for Mar 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Xenon
The Children's Hospital of Zhejiang University School of Medicine